

Vincent Wai-Sun Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8241949/publications.pdf>

Version: 2024-02-01

549
papers

55,132
citations

1371

108
h-index

1634

215
g-index

559
all docs

559
docs citations

559
times ranked

37451
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
2	Global Prevalence of <i>Helicobacter pylori</i> Infection: Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 153, 420-429.	1.3	1,983
3	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	1.3	1,840
4	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
5	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	7.3	1,294
6	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
7	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	7.3	1,203
8	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	7.3	1,052
9	Non-alcoholic fatty liver disease. <i>Lancet</i> , 2021, 397, 2212-2224.	13.7	1,035
10	Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. <i>Gut</i> , 2017, 66, 70-78.	12.1	865
11	New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873.	3.7	759
12	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
13	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	8.1	616
14	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.	30.5	612
15	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	1.3	575
16	Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. <i>New England Journal of Medicine</i> , 2005, 352, 238-244.	27.0	567
17	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	4.4	559
18	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1317-25.	7.1	543

#	ARTICLE	IF	CITATIONS
19	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	10.7	541
20	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010, 59, 969-974.	12.1	538
21	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	1.3	536
22	Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis. <i>New England Journal of Medicine</i> , 2002, 347, 2104-2110.	27.0	532
23	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	7.3	528
24	Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. <i>Journal of Clinical Virology</i> , 2004, 31, 304-309.	3.1	516
25	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. <i>Gut</i> , 2004, 53, 1494-1498.	12.1	455
26	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
27	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	12.1	423
28	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	4.2	422
29	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	8.1	411
30	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	7.3	408
31	Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 461-478.	17.8	400
32	Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding. <i>Annals of Internal Medicine</i> , 2010, 152, 1.	3.9	388
33	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	12.1	386
34	NAFLD in Asia – as common and important as in the West. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 307-318.	17.8	377
35	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	2.0	363
36	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 – Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358

#	ARTICLE	IF	CITATIONS
37	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2419-2440.	1.5	357
38	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
39	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	4.4	320
40	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 254-269.	3.7	320
41	Omeprazole before Endoscopy in Patients with Gastrointestinal Bleeding. <i>New England Journal of Medicine</i> , 2007, 356, 1631-1640.	27.0	312
42	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet</i> , The, 2007, 369, 1621-1626.	13.7	297
43	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.4	292
44	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	3.7	290
45	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
46	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	17.8	272
47	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	7.3	267
48	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	3.7	267
49	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study. <i>PLoS ONE</i> , 2013, 8, e62885.	2.5	266
50	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , 2017, 65, 54-64.	7.3	260
51	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. <i>Journal of Hepatology</i> , 2013, 59, 536-542.	3.7	254
52	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013, 12, 256-262.	1.5	252
53	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon- β 2b and Lamivudine with Lamivudine Alone. <i>Annals of Internal Medicine</i> , 2005, 142, 240.	3.9	248
54	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011, 60, 1721-1727.	12.1	248

#	ARTICLE	IF	CITATIONS
55	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1306-1314.	0.4	240
56	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	1.3	229
57	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 339-345.	3.7	227
58	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	7.3	227
59	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 1232-1241.	7.3	226
60	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011, 60, 829-836.	12.1	219
61	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , 2012, 56, 833-839.	3.7	218
62	Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2020, 72, 58-71.	7.3	209
63	Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. <i>Gastroenterology</i> , 2005, 128, 1890-1897.	1.3	207
64	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4138-4148.	1.5	206
65	Bacterial Microbiota Profiling in Gastritis without <i>Helicobacter pylori</i> Infection or Non-Steroidal Anti-Inflammatory Drug Use. <i>PLoS ONE</i> , 2009, 4, e7985.	2.5	204
66	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. <i>American Journal of Gastroenterology</i> , 2005, 100, 616-623.	0.4	200
67	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , 2017, 7, 45846.	3.3	199
68	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009, 58, 111-117.	12.1	198
69	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. <i>Journal of Hepatology</i> , 2012, 56, 1363-1370.	3.7	198
70	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 1349-1356.	3.7	198
71	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009, 124, 2766-2770.	5.1	197
72	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	7.3	197

#	ARTICLE	IF	CITATIONS
73	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	3.7	196
74	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
75	Fatty Pancreas, Insulin Resistance, and β^2 -Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.4	194
76	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	12.1	185
77	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	4.4	181
78	CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2014, 61, 1365-1375.	3.7	178
79	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
80	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	3.7	173
81	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	1.3	171
82	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1104-1112.	3.7	159
83	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019, 29, 418-427.	5.5	159
84	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	1.3	156
85	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. <i>Hepatology</i> , 2021, 73, 625-643.	7.3	156
86	Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment. <i>Gastroenterology</i> , 2013, 144, 933-944.	1.3	155
87	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	8.1	152
88	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	2.8	152
89	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. <i>Cancer Discovery</i> , 2020, 10, 664-673.	9.4	152
90	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	2.8	151

#	ARTICLE	IF	CITATIONS
91	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	3.7	147
92	Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. <i>Gastroenterology</i> , 2004, 127, 1038-1043.	1.3	143
93	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	4.4	143
94	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10925-E10933.	7.1	140
95	Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 163-172.	2.8	135
96	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
97	Laboratory parameter-based machine learning model for excluding nonalcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 447-456.	3.7	132
98	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-90.	1.6	131
99	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	8.1	130
100	High Incidence of Mortality and Recurrent Bleeding in Patients With Helicobacter pylori-Negative Idiopathic Bleeding Ulcers. <i>Gastroenterology</i> , 2009, 137, 525-531.	1.3	128
101	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 300-305.	2.8	127
102	Efficacy of Cap-Assisted Colonoscopy in Comparison With Regular Colonoscopy: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2009, 104, 41-46.	0.4	125
103	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	2.8	125
104	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 236-242.	3.7	122
105	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	12.1	121
106	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 278-285.	3.7	120
107	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	4.4	119
108	The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease guidelines 2017: Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117

#	ARTICLE	IF	CITATIONS
109	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014, 59, 986-995.	7.3	114
110	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.7	114
111	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 883-893.	3.7	113
112	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	3.7	113
113	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	12.1	113
114	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	3.7	112
115	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013, 12, 256-62.	1.5	111
116	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	4.0	110
117	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	3.7	110
118	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 387-396.	3.7	108
119	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 344-352.	3.7	107
120	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	4.4	107
121	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	7.3	107
122	Long-term Outcome of Helicobacter pylori–Negative Idiopathic Bleeding Ulcers: A Prospective Cohort Study. <i>Gastroenterology</i> , 2005, 128, 1845-1850.	1.3	105
123	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008, 28, 79-87.	3.9	105
124	Histone Deacetylase HDAC8 Promotes Insulin Resistance and β -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 4803-4816.	0.9	105
125	Treatment of Diarrhea-Predominant Irritable Bowel Syndrome with Traditional Chinese Herbal Medicine: A Randomized Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2006, 101, 1574-1580.	0.4	104
126	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	2.8	104

#	ARTICLE	IF	CITATIONS
127	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	3.7	104
128	Administrative Coding in Electronic Health Care Records—Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	7.3	102
129	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???.	0.4	101
130	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	7.3	101
131	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	7.3	101
132	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	1.3	101
133	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	7.3	100
134	Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients. <i>Antiviral Therapy</i> , 2011, 16, 1249-1257.	1.0	100
135	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1323-1331.	3.7	98
136	Distinct Clinical Characteristics Between Patients With Nonerosive Reflux Disease and Those With Reflux Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 690-695.	4.4	97
137	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. <i>Journal of Hepatology</i> , 2015, 63, 722-732.	3.7	97
138	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	4.2	96
139	<i>PNPLA3</i> gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 532-539.	3.7	95
140	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	2.8	95
141	NAFLD “sounding the alarm on a silent epidemic. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 377-379.	17.8	94
142	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.8	92
143	Modelling NAFLD disease burden in four Asian regions—2019–2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	3.7	92
144	Long-term Follow-up of Ulcerative Colitis in the Chinese Population. <i>American Journal of Gastroenterology</i> , 2009, 104, 647-654.	0.4	90

#	ARTICLE	IF	CITATIONS
145	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
146	Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 517-526.	3.7	89
147	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	9.6	88
148	Predicting Mortality in Patients With Bleeding Peptic Ulcers After Therapeutic Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 311-316.	4.4	86
149	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.4	83
150	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
151	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	3.7	83
152	Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. <i>Lancet, The</i> , 2017, 389, 2375-2382.	13.7	83
153	Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. <i>Gut</i> , 2022, 71, 716-723.	12.1	83
154	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1726-1731.	2.8	82
155	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	1.0	82
156	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	8.1	82
157	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	12.1	82
158	Histological progression of non-alcoholic fatty liver disease in Chinese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 407-413.	3.7	81
159	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	4.4	80
160	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 793-802.	3.7	79
161	From NAFLD to MAFLD: a redefining moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	2.3	79
162	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1357-1364.	7.3	77

#	ARTICLE	IF	CITATIONS
163	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015, 62, 684-693.	7.3	77
164	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	3.7	77
165	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	2.5	77
166	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	4.4	75
167	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2570-2580.e37.	4.4	75
168	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	3.9	75
169	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017, 65, 1840-1850.	7.3	74
170	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2011, 6, e22888.	2.5	73
171	Heme Oxygenase-1 Protects Against Steatohepatitis in Both Cultured Hepatocytes and Mice. <i>Gastroenterology</i> , 2010, 138, 694-704.e1.	1.3	72
172	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	3.7	72
173	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	17.8	72
174	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	4.4	70
175	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 128-141.	8.9	70
176	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	3.7	69
177	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017, 5, 76-85.	3.8	67
178	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.4	67
179	Lymphoepithelioma-like Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 304-312.	3.7	66
180	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, 5214.	12.8	66

#	ARTICLE	IF	CITATIONS
181	Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1179-1186.	2.8	65
182	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	4.4	65
183	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	4.4	64
184	Nonalcoholic fatty liver disease in Asia: A story of growth. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 18-23.	2.8	64
185	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2803-2820.	1.5	63
186	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.4	62
187	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , 2011, 46, 391-400.	5.1	62
188	Assessment of nonalcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	3.7	61
189	Noninvasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 197-208.	3.7	61
190	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018, 38, 503-514.	3.9	61
191	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020, 30, 1144-1153.	5.5	61
192	Genetic polymorphisms of adiponectin and tumor necrosis factor- α and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	2.8	60
193	Review article: long-term safety of oral antiviral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	3.7	60
194	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2018, 32, 37-51.	0.5	60
195	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018, 64, 1239-1249.	3.2	60
196	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	1.3	60
197	Evaluation of Model for End-Stage Liver Disease for Prediction of Mortality in Decompensated Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2006, 101, 1516-1523.	0.4	59
198	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 984-992.	3.7	59

#	ARTICLE	IF	CITATIONS
199	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	4.4	59
200	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	7.3	59
201	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2022, 76, 726-734.	3.7	59
202	Significant positive association of endotoxemia with histological severity in 237 patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 175-182.	3.7	58
203	Bacterial endotoxin and nonalcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 731-740.	3.7	57
204	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
205	Severe Acute Respiratory Syndrome in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1883-1888.	6.1	54
206	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. <i>Journal of Medical Virology</i> , 2010, 82, 1494-1500.	5.0	54
207	Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the GO ASIA initiative. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 816-825.	3.7	54
208	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	54
209	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	3.7	54
210	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007, 13, 1228-1235.	2.4	53
211	Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. <i>Gut</i> , 2014, 63, 1793-1804.	12.1	53
212	Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2011, 18, e29-39.	2.0	52
213	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	4.4	52
214	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020, 71, 444-455.	7.3	52
215	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	4.4	51
216	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 411-421.	3.7	51

#	ARTICLE	IF	CITATIONS
217	Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 45-49.	3.7	50
218	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. <i>Journal of Internal Medicine</i> , 2020, 287, 711-722.	6.0	50
219	Critical Role of Antimicrobial Peptide Cathelicidin for Controlling <i>Helicobacter pylori</i> Survival and Infection. <i>Journal of Immunology</i> , 2016, 196, 1799-1809.	0.8	49
220	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	3.7	49
221	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	4.4	49
222	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBsAg seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1326-1335.	3.7	48
223	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1001-1010.	3.7	48
224	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	4.4	48
225	Meta-analysis: reduction in hepatic events following interferon- α therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1059-1068.	3.7	47
226	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 989-1000.	3.7	47
227	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	4.4	47
228	Small bowel enteropathy associated with chronic low-dose aspirin therapy. <i>Lancet</i> , The, 2007, 369, 614.	13.7	46
229	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1113-1120.	4.4	46
230	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , 2014, 114, 754-760.	2.5	45
231	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	7.3	45
232	Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1405-1413.	2.8	44
233	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	2.8	44
234	Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 1203-1213.	12.1	44

#	ARTICLE	IF	CITATIONS
235	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	4.4	42
236	Invasive and non-invasive assessment of portal hypertension. <i>Hepatology International</i> , 2018, 12, 44-55.	4.2	42
237	Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 912-918.	3.7	41
238	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	7.3	41
239	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	7.3	41
240	HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1111-1119.	0.4	40
241	Can the same controlled attenuation parameter cutoffs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1787-1794.	2.8	40
242	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40
243	Artificial intelligence in prediction of nonalcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 543-550.	2.8	40
244	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	4.0	40
245	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 802-813.	3.7	39
246	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	12.1	39
247	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	2.8	39
248	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	5.8	39
249	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 891-898.	3.7	38
250	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	1.0	38
251	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 6515.	3.3	38
252	Modelling the economic and clinical burden of nonalcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	3.4	38

#	ARTICLE	IF	CITATIONS
253	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.4	37
254	Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. <i>Hepatology</i> , 2008, 47, 473-483.	7.3	36
255	Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4363-4369.	3.9	36
256	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019, 114, 1636-1641.	0.4	36
257	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	3.7	36
258	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	2.8	35
259	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	4.4	35
260	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014, 60, 809-815.	3.7	34
261	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. <i>Liver International</i> , 2018, 38, 636-644.	3.9	34
262	Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 53-53.	3.0	34
263	Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. <i>Journal of Digestive Diseases</i> , 2020, 21, 372-384.	1.5	34
264	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-499.	1.0	34
265	Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. <i>Journal of Pathology</i> , 2015, 237, 38-49.	4.5	33
266	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019, 70, 971-981.	7.3	33
267	On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 865-870.	4.4	33
268	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2022, 42, 149-160.	3.9	33
269	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 571-579.	1.0	33
270	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33

#	ARTICLE	IF	CITATIONS
271	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2014, 21, 825-834.	2.0	32
272	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	4.3	32
273	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	32
274	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011, 31, 1047-1053.	3.9	31
275	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016, 17, 538-546.	1.5	31
276	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154911.	3.4	31
277	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 145-153.	3.7	30
278	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, 2205-2211.	0.4	29
279	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005, 13, 175-182.	2.7	28
280	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.8	28
281	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	2.8	28
282	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	7.7	28
283	Treatment Candidacy for Pharmacologic Therapies for NASH. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1209-1217.	4.4	28
284	Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2014-2022.e4.	4.4	28
285	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	2.5	28
286	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-471.	1.0	28
287	Virological Response to Different Combination Regimes of Peginterferon α -2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-823.	1.0	28
288	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	12.1	27

#	ARTICLE	IF	CITATIONS
289	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 96-101.	3.7	26
290	Changing NAFLD Epidemiology in China. <i>Hepatology</i> , 2019, 70, 1095-1098.	7.3	26
291	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. <i>Liver Transplantation</i> , 2020, 26, 68-79.	2.4	26
292	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	5.8	26
293	Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 323-329.	3.7	25
294	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020, 20, 88.	2.0	25
295	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.4	25
296	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	4.4	24
297	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1629-1638.	0.4	24
298	Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 399-410.	2.4	24
299	Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target. <i>Gastroenterology</i> , 2021, 160, 2467-2482.e3.	1.3	24
300	Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. <i>Journal of Hepatology</i> , 2021, 75, 1267-1270.	3.7	24
301	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	7.3	24
302	Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 63-69.	2.8	23
303	Treatment of nonalcoholic steatohepatitis with <i>Phyllanthus urinaria</i> : A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	2.8	23
304	The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2015, 22, 328-334.	2.0	23
305	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016, 64, 1507-1517.	7.3	23
306	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk—a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1213-1224.	3.7	23

#	ARTICLE	IF	CITATIONS
307	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 271-279.	3.9	23
308	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 320-325.	2.8	23
309	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	3.7	23
310	Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 783-789.	2.8	22
311	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	3.9	22
312	A randomized comparison of ultrathin and standard colonoscope in cecal intubation rate and patient tolerance. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 484-490.	1.0	22
313	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	2.8	22
314	Mechanism and prediction of HCC development in HBV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 291-298.	2.4	22
315	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	2.2	22
316	Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B. <i>Digestive and Liver Disease</i> , 2018, 50, 787-794.	0.9	22
317	Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020, 55, 731-741.	5.1	22
318	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. <i>Clinical Chemistry</i> , 2022, 68, 1151-1163.	3.2	22
319	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: A seven-year follow-up study. <i>Journal of Medical Virology</i> , 2009, 81, 224-229.	5.0	21
320	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	2.9	21
321	Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2016, 64, 1211-1213.	3.7	21
322	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
323	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	4.4	21
324	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020, 4, 1624-1636.	4.3	21

#	ARTICLE	IF	CITATIONS
325	Metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 716-726.	3.7	20
326	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	2.9	20
327	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	7.3	20
328	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	2.5	20
329	Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3541-3547.	2.3	19
330	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2210-2219.	2.8	19
331	SGLT2 Inhibitors in Liver Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2168-2172.e2.	4.4	19
332	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 470-480.	3.7	19
333	Hepatocyte growth factor promotes proliferation and migration in immortalized progenitor cells. <i>NeuroReport</i> , 2008, 19, 765-769.	1.2	18
334	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.3	18
335	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	4.4	18
336	Collateral Effect of Coronavirus Disease 2019 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases: A Territory-wide Observational Study in Hong Kong. <i>Gastroenterology</i> , 2020, 159, 1979-1981.e3.	1.3	18
337	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.9	18
338	Virtual colonoscopy-induced perforation in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 978.	3.3	18
339	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	3.4	18
340	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	3.7	18
341	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic) Tj ETQq1 1 0.784314 rfgBT /Overlock 101	1.9	18
342	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17

#	ARTICLE	IF	CITATIONS
343	Eliminating hepatitis B virus as a global health threat. <i>Lancet Infectious Diseases</i> , 2016, 16, 1313-1314.	9.1	17
344	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir – A prospective study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 126-135.	2.0	17
345	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	2.0	17
346	Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	17
347	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , 2021, 11, e052310.	1.9	17
348	Non-invasive tests of non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2022, 135, 532-546.	2.3	17
349	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16
350	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	2.8	16
351	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2019, 70, 660-666.	5.8	16
352	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	6.1	16
353	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	4.3	16
354	Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 388-390.	1.5	16
355	Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1703-1711.	3.7	15
356	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , 2010, 47, 193-195.	3.1	15
357	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 972-981.	3.7	15
358	Diagnosis and personalized management of hepatitis B including significance of genotypes. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 570-577.	3.1	15
359	Current Prevention and Treatment Options for NAFLD. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 149-157.	1.6	15
360	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018, 38, 1911-1919.	3.9	15

#	ARTICLE	IF	CITATIONS
361	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 592-598.	2.8	14
362	A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , 2008, 15, 449-458.	2.0	14
363	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 122-129.	3.6	14
364	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	3.7	14
365	Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. <i>Gut</i> , 2020, 69, 652-657.	12.1	14
366	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.8	14
367	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020, 5, 1129-1138.	0.8	14
368	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	8.9	14
369	Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history. <i>International Journal of Cancer</i> , 2016, 138, 576-583.	5.1	13
370	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	2.8	13
371	Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 491-496.	0.9	13
372	NAFLD in lean individuals: not a benign disease. <i>Gut</i> , 2022, 71, 234-236.	12.1	13
373	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	4.3	13
374	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	1.0	12
375	Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 9-12.	2.3	12
376	Noninvasive assessments of liver fibrosis with transient elastography and F_{UI} index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	2.8	12
377	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016, 62, S298-S305.	5.8	12
378	Predicting NASH response with liver fat: Are we back to square one?. <i>Journal of Hepatology</i> , 2020, 72, 386-388.	3.7	12

#	ARTICLE	IF	CITATIONS
379	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	2.2	12
380	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	3.3	12
381	UA-CRNN: Uncertainty-Aware Convolutional Recurrent Neural Network for Mortality Risk Prediction. , 2019, , .		12
382	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	8.9	12
383	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	4.9	12
384	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon α 2a (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , 2008, 13, 555-562.	1.0	12
385	Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B?. <i>Journal of Hepatology</i> , 2002, 36, 177.	3.7	11
386	Initial Treatment With Lansoprazole in Young Dyspeptic Patients With Negative Urea Breath Test Result: A Randomized Controlled Trial With 12-Month Follow-Up. <i>American Journal of Gastroenterology</i> , 2007, 102, 1483-1488.	0.4	11
387	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	4.4	11
388	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2020, 40, 549-557.	3.9	11
389	Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 416-425.	1.3	11
390	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.9	11
391	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-93.	1.5	11
392	Liver Stiffness Measurement: Simplicity is Prerequisite for Reliability. <i>Gastroenterology</i> , 2013, 144, 243-244.	1.3	10
393	Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study. <i>Annals of Hepatology</i> , 2017, 16, 123-132.	1.5	10
394	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	2.8	10
395	LBO-03-Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e128.	3.7	10
396	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.9	10

#	ARTICLE	IF	CITATIONS
397	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. <i>BMC Gastroenterology</i> , 2016, 16, 100.	2.0	9
398	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	2.5	9
399	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	4.3	9
400	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2021, 67, 1492-1502.	3.2	9
401	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , 2020, 26, 2416-2426.	3.3	9
402	Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. <i>Liver International</i> , 2022, 42, 271-273.	3.9	9
403	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	4.4	9
404	Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine. <i>Antiviral Therapy</i> , 2013, 18, 671-680.	1.0	8
405	In search of new biomarkers for nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2016, 8, 19-23.	2.1	8
406	Fibroblast growth factor 21 for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2018, 392, 2658-2660.	13.7	8
407	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2202-2209.	2.8	8
408	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3487-3499.	2.8	8
409	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012, 57, 221-231.	2.3	7
410	Impact of <i>IL28B</i> and <i>PNPLA3</i> polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1040-1048.	2.8	7
411	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1190-1199.	3.7	7
412	A LEAN treatment for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2016, 387, 628-630.	13.7	7
413	How to identify patients with advanced liver disease in the community?. <i>Hepatology</i> , 2017, 66, 7-9.	7.3	7
414	An international survey on patterns of practice in NAFLD and expectations for therapies—the POP-NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777.	7.3	7

#	ARTICLE	IF	CITATIONS
415	Regression of Cirrhosis With Long-Term Tenofovir Treatment. <i>Gastroenterology</i> , 2013, 145, 481-482.	1.3	6
416	Huge Adrenal Hemangioma: A Rare Cause of Deceptively High Liver Stiffness Measurement by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e37-e38.	4.4	6
417	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1071-1078.	2.8	6
418	Non-alcoholic fatty liver disease in Asia: How is it different from the West?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1267-1268.	2.8	6
419	Macromolecular proton fraction mapping based on spin-echo magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 3157-3171.	3.0	6
420	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 128.	2.0	6
421	Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, 20, 78-84.	1.8	6
422	Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 273-277.	8.9	6
423	Interferon-induced thyroid dysfunction not always transient. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 938-940.	2.8	5
424	Editorial: when and how to use steatosis biomarkers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1359-1360.	3.7	5
425	Is Obeticholic Acid the Solution to Nonalcoholic Steatohepatitis?. <i>Gastroenterology</i> , 2015, 148, 851-852.	1.3	5
426	Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet?. <i>Hepatology</i> , 2017, 65, 8-11.	7.3	5
427	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	5.0	5
428	How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 103-105.	8.1	5
429	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	2.8	5
430	Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1131-1138.	2.8	5
431	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	5.0	5
432	Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs—what have we achieved so far?. <i>Digestive and Liver Disease</i> , 2004, 36, 1-3.	0.9	4

#	ARTICLE	IF	CITATIONS
433	Can dietetic intervention for obesity ever succeed in real life?. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 459-460.	2.8	4
434	Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet?. Journal of Gastroenterology, 2009, 44, 53-56.	5.1	4
435	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. Journal of Hepatology, 2011, 55, 497.	3.7	4
436	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 419-420.	2.8	4
437	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1610-1618.	2.8	4
438	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. , 2021, , .		4
439	Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy. Alimentary Pharmacology and Therapeutics, 2021, 54, 722-723.	3.7	4
440	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. BMJ Open, 2021, 11, e052310.	1.9	4
441	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. Liver International, 2022, 42, 1037-1048.	3.9	4
442	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2022, 28, 1563-1573.	3.3	4
443	Characterization and correction of the effects of hepatic iron on T_2^* relaxation in the liver at 3.0T. Magnetic Resonance in Medicine, 0, , .	3.0	4
444	Reply:. Hepatology, 2009, 50, 2049-2050.	7.3	3
445	Do we need a histological score to diagnose non-alcoholic steatohepatitis?. Alimentary Pharmacology and Therapeutics, 2011, 34, 494-495.	3.7	3
446	Application of transient elastography in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2011, 34, 817-818.	3.7	3
447	Is Modest Drinking Good for the Liver?. Clinical Gastroenterology and Hepatology, 2018, 16, 1404-1406.	4.4	3
448	A new bile acid treatment for non-alcoholic fatty liver disease. The Lancet Gastroenterology and Hepatology, 2019, 4, 747-749.	8.1	3
449	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. Liver International, 2019, 39, 494-502.	3.9	3
450	Alanine Aminotransferase Level: The Road to Normal in 2021. Hepatology Communications, 2021, 5, 1807-1809.	4.3	3

#	ARTICLE	IF	CITATIONS
451	Effectiveness of prophylactic clipping in preventing postpolypectomy bleeding in oral anticoagulant users: a propensity-score analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 96, 530-542.e1.	1.0	3
452	Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 1029-1037.	1.0	3
453	Antiviral therapy for chronic hepatitis B: are we doing any good to patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 223-226.	3.0	2
454	Hepatitis C virus infection and diabetes: Not a straightforward relationship. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1647-1648.	2.8	2
455	Commentary: coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1236-1237.	3.7	2
456	Mo1505 Meta-Analysis: Hepatocellular Carcinoma (HCC) Surveillance Adherence Rate (SAR) in High Risk Patients. <i>Gastroenterology</i> , 2016, 150, S1134.	1.3	2
457	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 260-262.	8.1	2
458	Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2192-2201.	2.8	2
459	A cirrhotic patient with fever and abdominal pain in the presence of ascites. <i>British Journal of Hospital Medicine</i> , 2003, 64, 310-310.	0.2	1
460	236 Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma. A prospective cohort study. <i>Journal of Hepatology</i> , 2004, 40, 75.	3.7	1
461	[489] SERUM HEPATITIS B SURFACE ANTIGEN (HBsAg) LEVEL CAN REFLECT HEPATITIS B VIRUS IN THE LIVER AND PREDICT TREATMENT RESPONSE. <i>Journal of Hepatology</i> , 2007, 46, S186.	3.7	1
462	277 TRANSIENT ELASTOGRAPHY (FIBROSCAN) CAN DETECT ADVANCED LIVER FIBROSIS BEST AMONG PATIENTS WITH NORMAL ALANINE TRANSAMINASE. <i>Journal of Hepatology</i> , 2008, 48, S111.	3.7	1
463	Medical therapy for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1135-1136.	3.7	1
464	PWE-293...Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general population—a randomised controlled trial. <i>Gut</i> , 2012, 61, A417.1-A417.	12.1	1
465	Commentary: predicting survival in hepatocellular carcinoma patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 680-680.	3.7	1
466	A New Era of Hepatitis C Treatment. <i>Gastroenterology</i> , 2012, 143, 264-265.	1.3	1
467	Non-invasive algorithms for liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 310-311.	3.7	1
468	Commentary: new tools to assess hepatic steatosis – what do we want to measure?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 293-293.	3.7	1

#	ARTICLE	IF	CITATIONS
469	Effects of placental HBV infection on the Parkinson 7 gene expression. <i>Placenta</i> , 2013, 34, A77-A78.	1.5	1
470	Commentary: nonalcoholic fatty pancreas – toward an uncharted territory. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 916-916.	3.7	1
471	Commentary: prognostication of chronic hepatitis B – are Fibrotest and Fibroscan the final answers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1113-1113.	3.7	1
472	Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting antivirals. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1427-1428.	3.7	1
473	Editorial: metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 983-983.	3.7	1
474	Reply. <i>Hepatology</i> , 2014, 60, 1797-1798.	7.3	1
475	Histone Deacetylase 8 Is a Novel Chromatin Modulator in NAFLD-Associated Hepatocarcinogenesis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 219.	4.4	1
476	Reply. <i>Hepatology</i> , 2016, 64, 685-686.	7.3	1
477	Oxidized low-density lipoprotein in nonalcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1516-1518.	2.8	1
478	Managing HCC in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 374-381.	0.9	1
479	Editorial: nonalcoholic fatty liver disease – it is better to be slender after all. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 305-306.	3.7	1
480	PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS \geq 4) and significant fibrosis (F \geq 2). <i>Journal of Hepatology</i> , 2019, 70, e134-e135.	3.7	1
481	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.6	1
482	Hepatobiliary and Pancreatic: A tree in the liver. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2337-2337.	2.8	1
483	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021, 4, e352.	1.5	1
484	2942 – Sofosbuvir (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design. <i>American Journal of Gastroenterology</i> , 2019, 114, S1601-S1602.	0.4	1
485	Abstract 2073: Histone deacetylase 8 impairs insulin sensitivity and activates β -catenin signaling in NAFLD-associated hepatocellular carcinoma. , 2015, , .		1
486	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	3.7	1

#	ARTICLE	IF	CITATIONS
487	Is lean non-alcoholic fatty liver disease a distinct entity?. <i>Hepatology International</i> , 2022, , 1.	4.2	1
488	Expression profilings of 39 genes selected by ANOVA could separate precursors of murine dendritic cells and macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2006, 344, 438-445.	2.1	0
489	921 IS THE ROADMAP MODEL COST-EFFECTIVE IN THE ERA OF TENOFOVIR IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION?. <i>Journal of Hepatology</i> , 2009, 50, S335.	3.7	0
490	Impact of Antiviral Therapy on Risk of Hepatocellular Carcinoma. <i>Current Hepatitis Reports</i> , 2010, 9, 47-52.	0.3	0
491	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	12.1	0
492	560 OBSTETRIC HISTORY AND THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN FEMALE CHRONIC HEPATITIS B CARRIERS. <i>Journal of Hepatology</i> , 2010, 52, S223.	3.7	0
493	723 A SIMPLE BREATH TEST CAN ASSESS LIVER FUNCTION AND PREDICT CLINICAL OUTCOME IN CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2010, 52, S281.	3.7	0
494	Commentary: time to update the <sc>ALT</sc> cutâ€ff?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 682-683.	3.7	0
495	Endoscopic Pancreatic Necrosectomy: Notes of Excitement. <i>Gastroenterology</i> , 2012, 143, 1114-1115.	1.3	0
496	606: Maternal HBeAg status and hepatitis B viral activity in HBsAg positive mothers. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, S273.	1.3	0
497	Tertiary Prevention of Hepatitis B-Related Hepatocellular Carcinoma: Do We Have a Verdict?. <i>Gastroenterology</i> , 2013, 144, 1142-1144.	1.3	0
498	Commentary: assessment of nonâ€alcoholic fatty liver disease using serum total cell death and apoptosis markers â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 276-276.	3.7	0
499	Letter: diagnostic accuracy of <sc>M</sc>30 levels for identifying patients with nonâ€alcoholic steatohepatitis â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 283-284.	3.7	0
500	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 298-298.	3.6	0
501	Commentary: dissecting the <i>PNPLA3</i> association with liver fat and stiffness, and interaction with diet â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 895-896.	3.7	0
502	Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease - authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1331-1332.	3.7	0
503	Su1031 High Liver Stiffness Measurement by Transient Elastography Predicts High Grade Post-Hepatectomy Liver Failure in Patients With Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Gastroenterology</i> , 2015, 148, S-1043.	1.3	0
504	Reply. <i>Hepatology</i> , 2016, 64, 1820-1821.	7.3	0

#	ARTICLE	IF	CITATIONS
505	Letter: is <scp>HIV</scp> infection an important factor for liver fibrosis? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 1002-1003.	3.7	0
506	Mo1490 Only One-Third of Patients With Hepatocellular Carcinoma (HCC) Were Diagnosed By Screening, Surveillance, or Without Symptoms: A Meta-Analysis of 40 Studies and 20,349 Patients With Diverse Underlying Liver Disease and World Regions. Gastroenterology, 2016, 150, S1129.	1.3	0
507	Letter: factors determining liver fibrosis - more to come. Alimentary Pharmacology and Therapeutics, 2016, 43, 171-172.	3.7	0
508	Letter: which patients with hepatitis B virusâ€related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 910-910.	3.7	0
509	Management of hepatitis Bâ€related cirrhosis in the era of effective antiviral therapy. Liver International, 2016, 36, 1752-1754.	3.9	0
510	Risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance â€ a territory-wide analysis of 5181 patients. Journal of Hepatology, 2017, 66, S15-S16.	3.7	0
511	Non-alcoholic fatty liver disease â€ demographic features, risk factors and treatment practices across the Asia Pacific region â€ the GO ASIA initiative. Journal of Hepatology, 2017, 66, S595.	3.7	0
512	Editorial: NAFLD in Asiaâ€clinical associations with advanced disease become clearer. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1037-1038.	3.7	0
513	Reply to: â€Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceâ€: Journal of Hepatology, 2018, 68, 208-209.	3.7	0
514	IDDF2018-ABS-0058â€...Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b â€ a territory-wide study of 21,182 subjects. , 2018, , .		0
515	Letter: chronic kidney disease risk in patients with chronic hepatitis Bâ€authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 1324-1324.	3.7	0
516	SAT-142-Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study. Journal of Hepatology, 2019, 70, e693.	3.7	0
517	THU-237-Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017. Journal of Hepatology, 2019, 70, e269.	3.7	0
518	THU-348-Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life. Journal of Hepatology, 2019, 70, e313.	3.7	0
519	SAT-147-Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis. Journal of Hepatology, 2019, 70, e696.	3.7	0
520	SAT-151-What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis?. Journal of Hepatology, 2019, 70, e697-e698.	3.7	0
521	SAT-072-Predict improvement of liver cirrhosis after antiviral treatment in patients with chronic hepatitis B. Journal of Hepatology, 2019, 70, e659.	3.7	0
522	Reply to: â€NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matterâ€: Journal of Hepatology, 2019, 70, 1304.	3.7	0

#	ARTICLE	IF	CITATIONS
523	IDDF2019-ABS-0199â€¦The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
524	IDDF2019-ABS-0131â€¦Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
525	IDDF2019-ABS-0133â€¦Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0
526	Reply to Sun et al. Clinical Infectious Diseases, 2020, 70, 2748-2749.	5.8	0
527	Reply:. Hepatology, 2020, 71, 1134-1134.	7.3	0
528	Reply to: â€œHepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the pageâ€• Journal of Hepatology, 2020, 73, 729-730.	3.7	0
529	Application of point shear wave elastography in alcohol-related liver disease. Hepatology International, 2020, 14, 161-163.	4.2	0
530	Editorial: increasing burden of nonalcoholic fatty liver diseaseâ€”a call to action. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1430-1432.	3.7	0
531	Chronic Hepatitis B Virus Infection: Noninvasive Assessment of Liver Disease. , 2021, , 251-266.		0
532	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong. Kidney360, 2021, 2, 721-728.	2.1	0
533	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 2684-2685.	4.4	0
534	Liverâ€”heart connection in diabetes mellitus. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1385-1386.	2.8	0
535	Reply. Hepatology, 2022, 75, 1051-1052.	7.3	0
536	IDDF2021-ABS-0122â€¦No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0
537	Targeting an energy sensor to prevent energy excess in the liver. The Lancet Gastroenterology and Hepatology, 2021, 6, 876-877.	8.1	0
538	Breastfeeding to Prevent NAFLD. Hepatology, 2021, 74, 2939-2941.	7.3	0
539	Abstract 5134: Histone deacetylase 8 is a novel chromatin modulator in NAFLD-associated hepatocarcinogenesis. , 2014, , .		0
540	Abstract 3752: A cell cycle-related kinase (CCRK) self-regulatory circuitry in NAFLD-associated hepatocarcinogenesis. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
541	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 508-508.	1.6	0
542	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , 2020, 26, 2415-2425.	3.3	0
543	IDDF2020-ABS-0200â€¦Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients. , 2020, , .		0
544	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , 2022, 2022, 1-13.	0.6	0
545	Reply. <i>Hepatology</i> , 2022, 76, E34-E35.	7.3	0
546	Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resectionâ€”Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1764-1764.	3.7	0
547	Editorial: metagenomeâ€œassembled genomes in nonâ€œalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 755-756.	3.7	0
548	Breakthroughs in hepatology. <i>Journal of Hepatology</i> , 2022, 76, 1247-1248.	3.7	0
549	Learning Sparse Interpretable Features For NAS Scoring From Liver Biopsy Images. , 2022, , .		0